|Home Page : www.otcjournal.com
Email Questions or Comments To: email@example.com
OTC Journal Members:
On April 23rd I published my first edition on Luxeyard (LUXR)- The edition was titled "Still 50% Undervalued". At the time, LUXR was $.80.
On May 8th, I published my last (not forever) edition on LUXR, where I disclosed I had sold my entire position in the stock - with the last trades being around the $2 level. The net gain for you over 2 weeks was about 150%. I wish they were all like that.
That's all very nice- but here's the point of today's edition. During the course of that two weeks, there was one pullback in the stock. The April 19th edition had a section entitled LUXR- You're Getting a Mulligan. The stock had abruptly traded down from $1.25 to about $.80. If you acted quickly, you had a second chance to jump in.
Here's the chart:
Learn from the past to make money in the future. The back half of this week is your mulligan in my by far current favorite idea- Barfresh (BRFH). This is Deja Vu all over again.
While there's no guarantee BRFH will be a perfect repeat of what happened last month with LUXR, I believe there's a good chance we'll see a repeat of the pattern. As I disclosed in my initial presentation, I am a very large shareholder of BRFH shares, but have not been paid in any way by the company.
I'm also plan to be very active both buying and selling in this security. Last week, I was a seller of a very small percentage of my position. Yesterday, I was buying it back, and will likely do so again today and/or later in the week if I am lucky enough to be able to acquire the shares in the $1 range.
Here's a chart:
In my initial presentation on May 13th, I described Barfresh (OTC: BRFH) as representing the "Most Profitable 7 Square Inches on Earth". I'm referring to the roughly 7 square inches a blender uses on the counter of a Quick Serve Restaurant.
Their product has taken Australia by storm.
Again, if nothing else, I strongly recommend you invest 5 minutes of your time to watch the video you can find at this web page:
You're getting a mulligan on this one. It's one of the better ideas you will read about for this entire year in the high risk, high return microcap sector.
If you missed LUXR, use this shallow pullback to take advantage of this one. I was yesterday, and could very well do so again today.
A reminder: Catch me live on TV every Monday from 12 to 2PM eastern.
The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies and receives compensation from them or third parties as payment for publishing information and opinions about the company and the trading market for their securities. Principals of the Newsletter may also purchase or sell securities of the companies in the open market from time to time. The positions, if any, that the Newsletter or its principals presently maintain in the securities of the companies are disclosed here (click here) and should be considered in making an investment decision regarding these companies securities. The Newsletter and its principals reserve the right to acquire additional shares or liquidate some or all of the positions they may hold in the issuer’s securities at any time in the future without further notice. These publications should not be considered to be independent publications concerning the company.
All statements and opinions expressed herein are those of the editors and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.
The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the express written consent of the editors of otcjournal.com.